- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Reston Today
By the People, for the People
New Nuclear Medicine Research Previewed for April 2026
The Journal of Nuclear Medicine highlights advances in PET imaging, Alzheimer's tracking, and targeted cancer therapy.
Apr. 4, 2026 at 7:24am
Got story updates? Submit your updates here. ›
Cutting-edge nuclear medicine and molecular imaging techniques are unlocking new possibilities for personalized diagnosis and treatment across a range of medical conditions.Reston TodayThe Journal of Nuclear Medicine has published new research ahead of its April 2026 issue, including studies on a novel PET tracer to measure synaptic density in epilepsy patients, faster whole-body PET scans to map cellular energy use, the use of tau PET imaging to track Alzheimer's progression, and targeted radiotherapy dosing for prostate cancer treatment.
Why it matters
These studies showcase how nuclear medicine and molecular imaging techniques are enabling more precise diagnosis, monitoring, and treatment of neurological disorders, cancer, and other diseases. The findings could lead to improved patient outcomes through personalized medicine approaches.
The details
The new PET tracer 18F-UCB-H was tested in 29 patients with drug-resistant focal epilepsy, revealing patterns of synaptic density that correlated with medication effects and lesion characteristics. Researchers also tracked the PET tracer 18F-flurpiridaz through the organs of 12 healthy volunteers, finding that shorter 10-minute scans closely matched full 60-minute results, supporting faster imaging approaches. In an Alzheimer's study, 18F-MK-6240 PET scans monitored tau buildup in 27 people over two years, showing faster accumulation in more impaired patients and links to worsening cognitive scores. Finally, the phase 2 LUNAR trial used 177Lu-PSMA-I&T targeted radiotherapy in 45 prostate cancer patients, with imaging tracking radiation doses to organs and 123 tumors to optimize treatment distribution.
- The new research was published ahead-of-print on April 3, 2026.
- The Journal of Nuclear Medicine is published monthly.
The players
The Journal of Nuclear Medicine (JNM)
A medical journal published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics.
Society of Nuclear Medicine and Molecular Imaging
An international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients.
What’s next
The full research articles will be published in the April 2026 issue of The Journal of Nuclear Medicine.
The takeaway
These studies demonstrate how advanced nuclear medicine and molecular imaging techniques are enabling more precise, personalized approaches to diagnosing, monitoring, and treating a range of medical conditions, from neurological disorders to cancer. The findings could lead to improved patient outcomes through tailored therapies.
